AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...

Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company's clinical development portfolio. "We delivered ...
NPR

Studio 2

On this episode of Studio 2, it’s the ultimate throwback summer: we’re bringing back some of our favorite memories from decades past. We’ll talk about the songs, snacks and hangouts that defined ...